Top ▲


Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1874

Nomenclature: CD40

Systematic Nomenclature: TNFRSF5

Family: Immune checkpoint catalytic receptors, Tumour necrosis factor (TNF) receptor family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 277 20q13.12 CD40 CD40 molecule
Mouse 1 289 2 85.38 cM Cd40 CD40 antigen
Rat - - Cd40 CD40 molecule
Previous and Unofficial Names Click here for help
CD40 molecule, TNF receptor superfamily member 5 | TNFRSF5
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
Natural/Endogenous Ligands Click here for help
CD40 ligand {Sp: Human}
Adaptor proteins (Human)

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
CFZ533 Peptide Primary target of this compound Immunopharmacology Ligand Hs Binding 9.2 pKd 1
pKd 9.2 (Kd 6.9x10-10 M) [1]
Description: Measured using a Biacore assay.
Antibody Comments
Other anti-CD40 mAbs in clinical development include ABBV-323 (ravagalimab; for Crohn's disease) and JNJ-64457107 (vanalimab, ADC-1013; a CD40 agonistic mAb in Phase 1 immuno-oncology trial NCT02829099)
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
CD40 ligand {Sp: Human} Peptide Ligand is endogenous in the given species Immunopharmacology Ligand Hs - - -
Immunopharmacology Comments
CD40 is a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). It is expressed on a variety of immune cells, including macrophages, B cells, and dendritic cells (DCs). CD40 plays a key role in the activation of the immune system. Endogenous ligand is CD154 (CD40L) on TH cells. CD40 is an immunotherapy and immuno-oncology clinical target. Anti-CD40 agonistic monoclonal antibodies that induce activation and proliferation of effector and memory T cells, and enhance the immune response against tumour cells, are in clinical development.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Cytokine production & signalling
Immuno Process:  Cellular signalling
Immuno Process:  T cell (activation)
Immuno Process:  Immune system development


Show »

1. Heusser C, Rush J, Vincent K. (2012) Silent fc variants of anti-cd40 antibodies. Patent number: WO2012065950. Assignee: Novartis Ag. Priority date: 15/11/2010. Publication date: 24/05/2012.

How to cite this page